Scarica l'app Stockscreener
0.8962
2.48%
-0.0228
Dopo l'orario di chiusura:
.90
0.0038
+0.42%
Precedente Chiudi:
$0.919
Aprire:
$0.9211
Volume 24 ore:
4.37M
Relative Volume:
0.73
Capitalizzazione di mercato:
$248.34M
Reddito:
$232.40M
Utile/perdita netta:
$-20.51M
Rapporto P/E:
-11.62
EPS:
-0.0771
Flusso di cassa netto:
$60.04M
1 W Prestazione:
-2.13%
1M Prestazione:
-6.49%
6M Prestazione:
-35.53%
1 anno Prestazione:
-66.93%
Intervallo 1D:
$0.8929
$0.9269
Intervallo di 1 settimana:
$0.8929
$1.00
Portata 52W:
$0.814
$3.20
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, TEVA, HLN, ZTS, VTRS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
0.8962 | 248.34M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights - Lelezard
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring A 337% Potential Upside - DirectorsTalk Interviews
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics Price Target Maintained With a $4.00/Share by BTIG - Moomoo
Akebia doses first patient in Phase 2 kidney disease trial By Investing.com - Investing.com South Africa
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial - marketscreener.com
Akebia doses first patient in Phase 2 kidney disease trial - Investing.com
One trial, three rare kidney diseases: Akebia doses its first patient - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages - marketbeat.com
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
CRM: Salesforce Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - marketbeat.com
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - marketbeat.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat
Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Earnings Per Share - careplusvn.com
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 55.5% EPS SurpriseSubscription Growth Report - careplusvn.com
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
AKBA Looks 1.6% Overvalued on GF Value™ - GuruFocus
AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode - GuruFocus
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlight - GuruFocus
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... - Yahoo Finance
Is Akebia Therapeutics Inc (AKBA) Overvalued After Q2 Earnings M - GuruFocus
Akebia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results - MarketBeat
Akebia Therapeutics: Q2 Earnings Snapshot - Barchart.com
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):